Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;25(6):e14179.
doi: 10.1111/tid.14179. Epub 2023 Nov 1.

Viral specific T cell therapy in kidney transplant recipients - A single-center experience

Manish Anand  1 , Jake Nysather  1 , Gregory McGraw  1 , Senu Apewokin  1 , Ruby Khoury  2 , Michael S Grimley  2 , Shalini Bumb  1 , Amit Govil  1
Affiliations

Viral specific T cell therapy in kidney transplant recipients - A single-center experience

Manish Anand et al. Transpl Infect Dis. 2023 Dec.

Abstract

Background: Viral infections such as adenovirus (ADV), BK virus (BKV), and cytomegalovirus (CMV) after kidney transplantation negatively impact outcomes in transplant recipients despite advancements in screening and antiviral therapy. We describe our experience of using the virus-specific T cell therapy (VSTs) in kidney transplant recipients (KTR) at our transplant center.

Methods: This is a retrospective, single center review of KTR with ADV, BKV and CMV infections between June 2021 and December 2022. These patients received third party VSTs as part of the management of infections. The immunosuppression, details of infection and outcome data were obtained from electronic medical records.

Results: Two cases of ADV infection resolved after one infusion of VSTs. The response rate of BKV and CMV infection was not as robust with close to 50% reduction in median viral load after VSTs. Out of 23 patients, two patients developed chronic allograft nephropathy from membranoproliferative glomerulonephritis and acute rejection.

Conclusion: Patients that are resistant to antivirals or who have worsening viremia despite conventional management may benefit from VSTs therapy to treat underlying viral infection. Additional studies are needed to ascertain efficacy and short- and long-term risks secondary to VSTs.

PubMed Disclaimer

References

REFERENCES

    1. Parajuli S, Jorgenson M, Meyers RO, Djamali A, Galipeau J. Role of virus-specific T Cell therapy for cytomegalovirus and BK infections in kidney transplant recipients. Kidney360. 2021;2(5):905-915. Published 2021 Mar 26. doi:10.34067/KID.0001572021
    1. Florescu DF, Schaenman JM, AST Infectious Diseases Community of Practice. Adenovirus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13527. doi:10.1111/ctr.13527
    1. Ison MG, Hayden RT. Adenovirus. Microbiol Spectr. 2016;4(4): doi:10.1128/microbiolspec.DMIH2-0020-2015
    1. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients - Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9): e13512. doi:10.1111/ctr.13512
    1. Purighalla R, Shapiro R, McCauley J, Randhawa P. BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis. 1995;26(4):671-673. doi:10.1016/0272-6386(95)90608-8

MeSH terms